Nonviral delivery systems for small interfering RNAs

Molecular Biology

Volumn 46, Issue 3, 2012, Pages 349-361

  Glebova, K V ^a   Marakhonov, A V ^a   Baranova, A V ^a,b   Skoblov, M Yu ^a  

^a RESEARCH CENTRE FOR MEDICAL GENETICS   (Russian Federation)

^b GEORGE MASON UNIVERSITY   (United States)

Author keywords

RNA interference; siRNA; siRNA delivery

Indexed keywords

EID: 84862330508     PISSN: 00268933     EISSN: 16083245     Source Type: Journal    
DOI: 10.1134/S0026893312020070     Document Type: Article

References (116)

1. Aigner A. J. 2006. Delivery systems for the direct application of siRNAs to induce RNA interference (RNAi) in vivo. Biomed. Biotechnol. 4, 71659.
2. Kim E. J., Shim G., Kim K., Kwon I. C., Oh Y. K., Shim C. K. 2009. Hyaluronic acid complexed to biodegradable poly L-arginine for targeted delivery of siRNAs. J. Gene Med. 11, 791-803.
3. Bumcrot D., Manoharan M., Koteliansky V., Sah D. W. 2006. RNAi therapeutics: A potential new class of pharmaceutical drugs. Nature Chem. Biol. 2, 711-719.
4. Akhtar S., Benter I. 2007. Toxicogenomics of nonviral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv. Drug Deliv. Rev. 59, 164-182.
5. Soriano P., Dijkstra J., Legrand A., Spanjer H., Londos-Gagliardi D., Roerdink F., Scherphof G., Nicolau C. 1983. Targeted and nontargeted liposomes for in vivo transfer to rat liver cells of a plasmid containing the preproinsulin I gene. Proc. Natl. Acad. Sci. U. S. A. 80, 7128-7131.
6. Felgner P. L., Ringold G. M. 1989. Cationic liposome-mediated transfection. Nature. 337, 387-388.
7. Ozpolat B., Sood A. K., Lopez-Berestein G. 2010. Nanomedicine-based approaches for the delivery of siRNA in cancer. J. Intern. Med. 267, 44-53.
8. Arnold A. S., Tang Y. L., Qian K., Shen L., Valencia V., Phillips M. I., Zhang Y. C. 2007. Specific beta1-adrenergic receptor silencing with small interfering RNA lowers high blood pressure and improves cardiac function in myocardial ischemia. J. Hypertens. 25, 197-205.
9. Sorensen D. R., Leirdal M., Sioud M. 2003. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J. Mol. Biol. 327, 761-766.
10. Peng P. H., Huang H. S., Lee Y. J., Chen Y. S., Ma M. C. 2009. Novel role for the delta-opioid receptor in hypoxic preconditioning in rat retinas. J. Neurochem. 108, 741-754.
11. Murata M., Takanami T., Shimizu S., Kubota Y., Horiuchi S., Habano W., Ma J. X., Sato S. 2006. Inhibition of ocular angiogenesis by diced small interfering RNAs (siRNAs) specific to vascular endothelial growth factor (VEGF). Curr. Eye Res. 31, 171-180.
12. Baker-Herman T. L., Fuller D. D., Bavis R. W., Zabka A. G., Golder F. J., Doperalski N. J., Johnson R. A., Watters J. J., Mitchell G. S. 2004. BDNF is necessary and sufficient for spinal respiratory plasticity following intermittent hypoxia. Nature Neurosci. 7, 48-55.
13. Nakamura H., Siddiqui S. S., Shen X., Malik A. B., Pulido J. S., Kumar N. M., Yue B. Y. 2004. RNA interference targeting transforming growth factor-beta type II receptor suppresses ocular inflammation and fibrosis. Mol. Vis. 10, 703-711.
14. Verma U. N., Surabhi R. M., Schmaltieg A., Becerra C., Gaynor R. B. 2003. Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin. Cancer Res. 9, 1291-1300.
15. Chien P. Y., Wang J., Carbonaro D., Lei S., Miller B., Sheikh S., Ali S. M., Ahmad M. U., Ahmad I. 2005. Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo. Cancer Gene Ther. 12, 321-328.
16. Khoury M., Louis-Plence P., Escriou V., Noel D., Largeau C., Cantos C., Scherman D., Jorgensen C., Apparailly F. 2006. Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis. Arthr. Rheum. 54, 1867-1877.
17. Miyawaki-Shimizu K., Predescu D., Shimizu J., Broman M., Predescu S., Malik A. B. 2006. siRNA-induced caveolin-1 knockdown in mice increases lung vascular permeability via the junctional pathway. Am. J. Physiol. Lung Cell Mol. Physiol. 290, L405-L413.
18. Chono S., Li S. D., Conwell C. C. Huang L. 2008. An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. J. Control. Release. 131, 64-69.
19. Wu S. Y., McMillan N. A. 2009. Lipidic systems for in vivo siRNA delivery. AAPS J. 11, 639-652.
20. Judge A. D., Robbins M., Tavakoli I., Levi J., Hu L., Fronda A., Ambegia E., McClintock K., MacLachlan I. 2009. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J. Clin. Invest. 119, 661-673.
21. Carmona S., Jorgensen M. R., Kolli S., Crowther C., Salazar F. H., Marion P. L., Fujino M., Natori Y., Thanou M., Arbuthnot P., Miller A. D. 2009. Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles. Mol. Pharm. 6, 706-717.
22. Akinc A., Zumbuehl A., Goldberg M., Leshchiner E. S., Busini V., Hossain N., Bacallado S. A., Nguyen D. N., Fuller J., Alvarez R., Borodovsky A., Borland T., Constien R., de Fougerolles A., Dorkin J. R., Narayanannair J. K, Jayaraman M., John M., Koteliansky V., Manoharan M., Nechev L., Qin J., Racie T., Raitcheva D., Rajeev K. G., Sah D. W., Soutschek J., Toudjarska I., Vornlocher H. P., Zimmermann T. S., Langer R., Anderson D. G. 2008. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nature Biotechnol. 26, 561-569.
23. Pirollo K. F., Rait A., Zhou Q., Hwang S. H., Dagata J. A., Zon G., Hogrefe R. I., Palchik G., Chang E. H. 2007. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res. 67, 2938-2943.
24. Gilmore I. R., Fox S. P., Hollins A. J., Sohail M., Akhtar S. 2004. The design and exogenous delivery of siRNA for post-transcriptional gene silencing. J. Drug Target. 12, 315-340.
25. Gilmore I. R., Fox S. P., Hollins A. J., Akhtar S. 2006. Delivery strategies for siRNA-mediated gene silencing. Curr. Drug Deliv. 3, 147-155.
26. Omidi Y., Hollins A. J., Benboubetra M., Drayton R., Benter I. F., Akhtar S. 2003. Toxicogenomics of non-viral vectors for gene therapy: A microarray study of lipofectin- and oligofectamine-induced gene expression changes in human epithelial cells. J. Drug Target. 11, 311-323.
27. Judge A. D., Sood V., Shaw J. R., Fang D., McClintock K., MacLachlan I. 2005. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nature Biotechnol. 23, 457-462.
28. Ikeda Y., Taira K. 2006. Ligand-targeted delivery of therapeutic siRNA. Pharm. Res. 23, 1631-1640.
29. Leng Q., Woodle M. C., Lu P. Y., Mixson A. J. 2009. Advances in systemic siRNA delivery. Drugs Future. 34, 721.
30. Landen C. N. Jr., Chavez-Reyes A., Bucana C., Schmandt R., Deavers M. T., Lopez-Berestein G., Sood A. K. 2005. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65, 6910-6918.
31. Halder J., Kamat A. A., Landen C. N. Jr., Han L. Y., Lutgendorf S. K., Lin Y. G., Merritt W. M., Jennings N. B., Chavez-Reyes A., Coleman R. L., Gershenson D. M., Schmandt R., Cole S. W., Lopez-Berestein G., Sood A. K. 2006. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin. Cancer Res. 12, 4916-4924.
32. Gray M. J., van Buren G., Dallas N. A. Xia L., Wang X., Yang A. D., Somcio R. J., Lin Y. G., Lim S., Fan F., Mangala L. S., Arumugam T., Logsdon C. D., Lopez-Berestein G., Sood A. K., Ellis L. M. 2008. Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J. Natl. Cancer Inst. 100, 109-120.
33. Merritt W. M., Lin Y. G., Spannuth W. A., Fletcher M. S., Kamat A. A., Han L. Y., Landen C. N., Jennings N., de Geest K., Langley R. R., Villares G., Sanguino A., Lutgendorf S. K., Lopez-Berestein G., Bar-Eli M. M., Sood A. K. 2008. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J. Natl. Cancer Inst. 100, 359-372.
34. Ozpolat B., Akar U., Tekedereli I., Lopez-Berestein G. 2008. Targeted silencing of Bcl-2 by liposomal siRNA-nanovectors leads to autophagic and apoptotic cell death in in vivo breast cancer models. Proc. Am. Assoc. Cancer Res. 4928.
35. Gewirtz A. M. 2007. On future's doorstep: RNA interference and the pharmacopeia of tomorrow. J. Clin. Invest. 117, 3612-3614.
36. Zimmermann T. S., Lee A. C., Akinc A., Bramlage B., Bumcrot D., Fedoruk M. N., Harborth J., Heyes J. A., Jeffs L. B., John M., Judge A. D., Lam K., McClintock K., Nechev L. V., Palmer L. R., Racie T., Röhl I., Seiffert S., Shanmugam S., Sood V., Soutschek J., Toudjarska I., Wheat A. J., Yaworski E., Zedalis W., Koteliansky V., Manoharan M., Vornlocher H. P., MacLachlan I. 2006. RNAi-mediated gene silencing in non-human primates. Nature. 441, 111-114.
37. Gabizon A. A., Shmeeda H., Zalipsky S. 2006. Pros and cons of the liposome platform in cancer drug targeting. J. Liposome Res. 16, 175-183.
38. Sharpe M., Easthope S. E., Keating G. M., Lamb H. M. 2002. Polyethylene glycol-liposomal doxorubicin: A review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma. Drugs. 62, 2089-2126.
39. Ishida T., Wang X., Shimizu T., Nawata K., Kiwada H. 2007. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J. Control. Release. 122, 349-355.
40. Semple S. C., Harasym T. O., Clow K. A., Ansell S. M., Klimuk S. K., Hope M. J. 2005. Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic acid. J. Pharmacol. Exp. Ther. 312, 1020-1026.
41. Judge A. D., Bola G., Lee A. C., MacLachlan I. 2006. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol. Ther. 13, 494-505.
42. Morrissey D. V., Lockridge J. A., Shaw L., Blanchard K., Jensen K., Breen W., Hartsough K., Machemer L., Radka S., Jadhav V., Vaish N., Zinnen S., Vargeese C., Bowman K., Shašer C. S., Ješs L. B., Judge A., MacLachlan I., Polisky B. 2005. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nature Biotechnol. 23, 1002-1007.
43. Jeffs L. B., Palmer L. R., Ambegia E. G., Giesbrecht C., Ewanick S., MacLachlan I. 2005. A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA. Pharm. Res. 22, 362-372.
44. Rozema D. B., Lewis D. L., Wakefield D. H., Wong S. C., Klein J. J., Roesch P. L., Bertin S. L., Reppen T. W., Chu Q., Blokhin A. V., Hagstrom J. E., Wolff J. A. 2007. Dynamic Polyconjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc. Natl. Acad. Sci. U. S. A. 104, 12982-1287.
45. Peer D., Park E. J., Morishita Y., Carman C. V., Shimaoka M. 2008. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science. 319, 627-630.
46. Yagi N., Manabe I., Tottori T., Ishihara A., Ogata F., Kim J. H., Nishimura S., Fujiu K., Oishi Y., Itaka K., Kato Y., Yamauchi M., Nagai R. 2009. A nanoparticle system specifically designed to deliver short interfering RNA inhibits tumor growth in vivo. Cancer Res. 69, 6531-6538.
47. Alvarez-Erviti L., Seow Y., Yin H., Betts C., Lakhal S., Wood M. J. 2011. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nature Biotechnol. 29, 341-345.
48. Midoux P., Pichon C., Yaouanc J. J., Jaffrès P. A. 2009. Chemical vectors for gene delivery: A current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers. Br. J. Pharmacol. 157, 166-178.
49. Ashihara E., Kawata E., Maekawa T. 2010. Future prospect of RNA interference for cancer therapies. Curr. Drug Targets. 11, 345-360.
50. Ochiya T., Nagahara S., Sano A., Itoh H., Terada M. 2001. Biomaterials for gene delivery: Atelocollagen-mediated controlled release of molecular medicines. Curr. Gene Ther. 1, 31-52.
51. Sano A., Maeda M., Nagahara S., Ochiya T., Honma K., Itoh H., Miyata T., Fujioka K. 2003. Atelocollagen for protein and gene delivery. Adv. Drug Deliv. Rev. 55, 1651-1677.
52. Takeshita F., Ochiya T. 2006. Therapeutic potential of RNA interference against cancer. Cancer Sci. 97, 689-696.
53. Minakuchi Y., Takeshita F., Kosaka N., Sasaki H., Yamamoto Y., Kouno M., Honma K., Nagahara S., Hanai K., Sano A., Kato T., Terada M., Ochiya T. 2004. Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res. 32, e109.
54. Takeshita F., Minakuchi Y., Nagahara S., Honma K., Sasaki H., Hirai K., Teratani T., Namatame N., Yamamoto Y., Hanai K., Kato T., Sano A., Ochiya T. 2005. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc. Natl. Acad. Sci. U. S. A. 102, 12177-12182.
55. Takei Y., Kadomatsu K., Yuzawa Y., Matsuo S., Muramatsu T. 2004. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res. 64, 3365-3370.
56. Kawata E., Ashihara E., Kimura S., Takenaka K., Sato K., Tanaka R., Yokota A., Kamitsuji Y., Takeuchi M., Kuroda J., Tanaka F., Yoshikawa T., Maekawa T. 2008. Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer. Mol. Cancer Ther. 7, 2904-2912.
57. Chen Y., Liu Y. 2010. Cyclodextrin-based bioactive supramolecular assemblies. Chem. Soc. Rev. 39, 495-505.
58. Uekama K., Hirayama F., Irie T. 1998. Cyclodextrin drug carrier systems. Chem. Rev. 98, 2045-2076.
59. Hu-Lieskovan S., Heidel J. D., Bartlett D. W., Davis M. E., Triche T. J. 2005. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 65, 8984-8992.
60. Davis M. E., Pun S. H., Bellocq N. C., Reineke T. M., Popielarski S. R., Mishra S., Heidel J. D. 2004. Self-assembling nucleic acid delivery vehicles via linear, water-soluble, cyclodextrin-containing polymers. Curr. Med. Chem. 11, 179-197.
61. Heidel J. D., Yu Z., Liu J. Y., Rele S. M., Liang Y., Zeidan R. K., Kornbrust D. J., Davis M. E. 2007. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl. Acad. Sci. U. S. A. 104, 5715-5721.
62. Illum L. 2003. Nasal drug delivery: Possibilities, problems and solutions. J. Control. Release. 87, 187-198.
63. Howard K. A., Rahbek U. L., Liu X., Damgaard C. K., Glud S. Z., Andersen M. O., Hovgaard M. B., Schmitz A., Nyengaard J. R., Besenbacher F., Kjems J. 2006. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol. Ther. 14, 476-484.
64. Pille J. Y., Li H., Blot E. Bertrand J. R., Pritchard L. L., Opolon P., Maksimenko A., Lu H., Vannier J. P., Soria J., Malvy C., Soria C. 2006. Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. Hum. Gene Ther. 17, 1019-1026.
65. Kumar P., Wu H., McBride J. L., Junq K. E., Kim M. H., Davidson B. L., Lee S. K., Shankar P., Manjunath N. 2007. Transvascular delivery of small interfering RNA to the central nervous system. Nature. 448, 39-43.
66. Song E., Zhu P., Lee S. K., Chowdhury D., Kussman S., Dykxhoorn D. M., Feng Y., Palliser D., Weiner D. B., Shankar P., Marasco W. A., Lieberman J. 2005. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nature Biotechnol. 23, 709-717.
67. Peer D., Zhu P., Carman C. V., Lieberman J., Shimaoka M. 2007. Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc. Natl. Acad. Sci. U. S. A. 104, 4095-4100.
68. Urban-Klein B., Werth S., Abuharbeid S., Czubayko F., Aigner A. 2005. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 12, 461-466.
69. Thomas M., Lu J. J., Ge Q., Zhang C., Chen J., Klibanov A. M. 2005. Full deacylation of polyethylenimine dramatically boosts its gene delivery efficiency and specificity to mouse lung. Proc. Natl. Acad. Sci. U. S. A. 102, 5679-5684.
70. Read M. L., Singh S., Ahmed Z., Stevenson M., Briggs S. S., Oupicky D., Barrett L. B., Spice R., Kendall M., Berry M., Preece J. A., Logan A., Seymour L. W. 2005. A versatile reducible polycation-based system for efficient delivery of a broad range of nucleic acids. Nucleic Acids Res. 33, e86.
71. Fischer D., Bieber T., Li Y., Elsasser H. P., Kissel T. 1999. A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. Pharm. Res. 16, 1273-1279.
72. Marschall P., Malik N., Larin Z. 1999. Transfer of YACs up to 2. 3 Mb intact into human cells with polyethylenimine. Gene Ther. 6, 1634-1637.
73. Godbey W. T., Barry M. A., Saggau P., Wu K. K., Mikos A. G. 2000. Poly(ethylenimine)-mediated transfection: A new paradigm for gene delivery. J. Biomed. Mater. Res. 51, 321-328.
74. Harpe A. V., Petersen H., Li Y., Kissel T. 2000. Characterization of commercially available and synthesized polyethylenimines for gene delivery. J. Control. Release. 69, 309-322.
75. Kunath K., Harpe A. V., Fischer D., Petersen H., Bickel U., Voigt K., Kissel T. 2003. Low-molecular-weight polyethylenimine as a non-viral vector for DNA delivery: Comparison of physicochemical properties, transfection efficiency, and in vivo distribution with high-molecular-weight polyethylenimine. J. Control. Release. 89, 113-125.
76. Zintchenko A., Philipp A., Dehshahri A., Wagner E. 2008. Simple modifications of branched PEI lead to highly efficient siRNA carriers with low toxicity. Bioconjug. Chem. 19, 1448-1455.
77. Han S., Mahato R. I., Kim S. W. 2001. Water-soluble lipopolymer for gene delivery. Bioconjug. Chem. 12, 337-345.
78. Kim D. H., Rossi J. J. 2007. Strategies for silencing human disease using RNA interference. Nature Rev. Genet. 8, 173-184.
79. Jeong J. H., Christensen L. V., Yockman J. W., Zhong Z., Engbersen J. F., Kim W. J., Feijen J., Kim S. W. 2007. Reducible poly(amido ethylenimine) directed to enhance RNA interference. Biomaterials. 28, 1912-1917.
80. Breunig M., Hozsa C., Lungwitz C. U., Watanabe K., Umeda I., Kato H., Goepferich A. 2008. Mechanistic investigation of poly(ethylene imine)-based siRNA delivery: Disulfide bonds boost intracellular release of the cargo. J. Control. Release. 130, 57-63.
81. Schiffelers R. M., Ansari A., Xu J., Zhou Q., Tang Q., Storm G., Molema G., Lu P. Y., Scaria P. V., Woodle M. C. 2004. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32, e149.
82. Kim S. H., Jeong J. H., Lee S. H., Kim S. W., Park T. G. 2008. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J. Control. Release. 129, 107-16.
83. Leng Q., Woodle M. C., Lu P. Y., Mixson A. J. 2009. Advances in systemic siRNA delivery. Drugs Future. 34, 721.
84. Perales J. C., Ferkol T., Beegen H., Ratnoff O. D., Hanson R. W. 1994. Gene transfer in vivo: Sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake. Proc. Natl. Acad. Sci. U. S. A. 91, 4086-4090.
85. Ferkol T., Perales J. C., Mularo F., Hanson R. W. 1996. Receptor-mediated gene transfer into macrophages. Proc. Natl. Acad. Sci. U. S. A. 93, 101-105.
86. Stevenson M., Ramos-Perez V., Singh S., Soliman M., Preece J. A., Briggs S. S, Read M. L., Seymour L. W. 2008. Delivery of siRNA mediated by histidine-containing reducible polycations. J. Control. Release. 130, 46-56.
87. Midoux P., Pichon C., Yaouanc J. J., Jaffrès P. A. 2009. Chemical vectors for gene delivery: A current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers. Br. J. Pharmacol. 157, 166-78.
88. Midoux P., Monsigny M. 1999. Efficient gene transfer by histidylated polylysine/pDNA complexes. Bioconjug. Chem. 10, 406-411.
89. Chen Q. R., Zhang L., Stass S. A., Mixson A. J. 2001. Branched co-polymers of histidine and lysine are efficient carriers of plasmids. Nucleic Acids Res. 29, 1334-1340.
90. Stevenson M., Ramos-Perez V., Singh S., Soliman M., Preece J. A., Briggs S. S., Read M. L., Seymour L. W. 2008. Delivery of siRNA mediated by histidine-containing reducible polycations. J. Control. Release. 130, 46-56.
91. Meyer M., Dohmen C., Philipp A., Kiener D., Maiwald G., Scheu C., Ogris M., Wagner E. 2009. Synthesis and biological evaluation of a bioresponsive and endosomolytic siRNA-polymer conjugate. Mol. Pharm. 6, 752-762.
92. Leng Q., Scaria P., Zhu J., Ambulos N., Campbell P., Mixson A. J. 2005. Highly branched HK peptides are effective carriers of siRNA. J. Gene Med. 7, 977-986.
93. Leng Q., Scaria P., Lu P., Woodle M. C., Mixson A. J. 2008. Systemic delivery of HK Raf-1 siRNA polyplexes inhibits MDA-MB-435 xenografts. Cancer Gene Ther. 15, 485-495.
94. Yan Z., Zou H., Tian F., Grandis J. R., Mixson A. J., Lu P. Y., Li L. Y. 2008. Human rhomboid family-1 gene silencing causes apoptosis or autophagy to epithelial cancer cells and inhibits xenograft tumor growth. Mol. Cancer Ther. 7, 1355-1364.
95. Sun C., Lee J. S., Zhang M. 2008. Magnetic nanoparticles in MR imaging and drug delivery. Adv. Drug Deliv. Rev. 60, 1252-1265.
96. Lee J. H., Lee K., Moon S. H., Lee Y., Park T. G., Cheon J. 2009. All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery. Angew. Chem. Int. Ed. Engl. 48, 4174-4179.
97. Radu D. R., Lai C. Y., Jeftinija K., Rowe E. W., Jeftinija S., Lin V. S. 2004. A polyamidoamine dendrimer-capped mesoporous silica nanosphere-based gene transfection reagent. J. Am. Chem. Soc. 126, 13216-13217.
98. Yang J., Lee J., Kang J., Lee K., Suh J. S., Yoon H. G., Huh Y. M., Haam S. 2008. Hollow silica nanocontainers as drug delivery vehicles. Langmuir. 24, 3417-3421.
99. Xia T., Kovochich M., Liong M., Meng H., Kabehie S., George S., Zink J. I., Nel A. E. 2009. Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs. ACS Nano. 3, 3273-3286.
100. Zhang Z., Yang X., Zhang Y., Zeng B., Wang S., Zhu T., Roden R. B., Chen Y., Yang R. 2006. Delivery of telomerase reverse transcriptase small interfering RNA in complex with positively charged single-walled carbon nanotubes suppresses tumor growth. Clin. Cancer Res. 12, 4933-4939.
101. Yang R., Yang X., Zhang Z., Zhang Y., Wang S., Cai Z., Jia Y., Ma Y., Zheng C., Lu Y., Roden R., Chen Y. 2007. Retraction: Single-walled carbon nanotubes-mediated in vivo and in vitro delivery of siRNA into antigen-presenting cells. Gene Ther. 14, 920.
102. Podesta J. E., Al-Jamal K. T., Herrero M. A., Tian B., Ali-Boucetta H., Hegde V., Bianco A., Prato M., Kostarelos K. 2009. Antitumor activity and prolonged survival by carbon-nanotube-mediated therapeutic siRNA silencing in a human lung xenograft model. Small. 5, 1176-1185.
103. Bonoiu A. C., Mahajan S. D., Ding H., Roy I., Yong K. T., Kumar R., Hu R., Bergey E. J., Schwartz S. A., Prasad P. N. 2009. Nanotechnology approach for drug addiction therapy: gene silencing using delivery of gold nanorod-siRNA nanoplex in dopaminergic neurons. Proc. Natl. Acad. Sci. U. S. A. 106, 5546-5550.
104. Manoharan M. 2004. RNA interference and chemically modified small interfering RNAs. Curr. Opin. Chem. Biol. 8, 570-579.
105. Chiu Y. L., Ali A., Chu C. Y., Cao H., Rana T. M. 2004. Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem. Biol. 11, 1165-1175.
106. Kumar R., Conklin D. S., Mittal V. 2003. High-throughput selection of effective RNAi probes for gene silencing. Genome Res. 13, 2333-2340.
107. Wu X., Liu H., Liu J., Haley K. N., Treadway J. A., Larson J. P., Ge N., Peale F., Bruchez M. P. 2003. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nature Biotechnol. 21, 41-46.
108. Dahan M., Levi S., Luccardini C., Rostaing P., Riveau B., Triller A. 2003. Diffusion dynamics of glycine receptors revealed by single-quantum dot tracking. Science. 302, 442-445.
109. Tsien R. Y. 1998. The green fluorescent protein. Annu. Rev. Biochem. 67, 509-544.
110. Chen A. A., Derfus A. M., Khetani S. R., Bhatia S. N. 2005. Quantum dots to monitor RNAi delivery and improve gene silencing. Nucleic Acids Res. 33, e190.
111. Medarova Z., Pham W., Farrar C., Petkova V., Moore A. 2007. In vivo imaging of siRNA delivery and silencing in tumors. Nature Med. 13, 372-377.
112. Marakhonov A. V., Serzhanova V. A., Skoblov M. Yu., Baranova A. V. 2010. Development of a system for testing siRNA vehicles. Med. Genet. 9, 12-15.
113. Marakhonov A. V., Baranova A. V., Skoblov M. Yu. 2008. RNA interference: Findamental and applied aspects. Med. Genet. 7, 44-56.
114. Skoblov M. Yu. 2009. Prospects of antisence therapy technologies. Mol. Biol. (Moscow). 43, 917-929.
115. Wang Y., Li Z., Han Y., Liang L. H., Ji A. 2010. Nanoparticle-based delivery system for application of siRNA in vivo. Curr. Drug Metab. 11, 182-196.
116. U. S. National Library of Medicine. A service of the U. S. National Institute of Health: ClinicalTrials. gov. http://clinicaltrials. gov/ct2/results?term=siRNA&show_flds=Y. Accessed Janurary 10, 2010.